Endocrinology

 

Dr. Barbour completed medical school at the University of Colorado in 1984 and accepted an internal medicine residency at the same institution from 1984-1987. She joined the faculty in the division of General Internal Medicine in 1987 and received a co-appointment in the Department of Obstetrics and Gynecology as an assistant professor in 1991 due to her role as medicine consultant for High Risk Obstetrics and Co-Director of their High Risk OB and Diabetes in Pregnancy Clinics. In 1992, she completed a fellowship in the Department of Preventive Medicine and Biometrics and received a Masters of Science in Public Health. Dr. Barbour was promoted to associate professor in Medicine and Obstetrics and Gynecology in 1996 with joint positions in the General Internal Medicine division and Maternal-Fetal-Medicine division. Due to her increasing interest in the area of endocrinology of pregnancy and translational research, she left the General Internal Medicine division in July of 1999 and pursued a fellowship at UCHSC in the division of Endocrinology, Metabolism, and Diabetes. She completed the three year fellowship in June of 2002, became board certified in Endocrinology, and is currently an associate professor in the divisions of Endocrinology, Metabolism, and Diabetes and Maternal-Fetal-Medicine. She has been awarded a K-23 grant to study insulin signaling in women with gestational diabetes during pregnancy and in the postpartum period. She is Past President of the North American Society of Obstetric Medicine, has served on the Pregnancy Council for the American Diabetes Association, and chaired the Colorado Clinical Guidelines Collaborative for Management of Gestational Diabetes for the state health department. She is a co-editor of the textbook “Medical Care of the Pregnant Patient”, for which the 2^nd edition will soon be released and is a co-author of the Endocrine Society Guidelines on Thyroid Disease in Pregnancy, also in press

Selected Publications

·         Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B, O M.  Growth Hormone Regulation of p85{alpha} Expression and Phosphoinositide 3-Kinase Activity in Adipose Tissue: Mechanism for Growth Hormone-Mediated Insulin Resistance. Diabetes. 2007 PUBMED

 ·        Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA.  Predictors of glyburide failure in the treatment of gestational diabetes.  Obstet Gynecol 2006:107(6):1303-9. PUBMED

·         Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. .  Increased p85α is a potent negative regulator of skeletal muscle insulin signaling and induces in-vivo insulin resistance associated with growth hormone excess.  JBC 2005;280:45:37489-94. PUBMED

·         Barbour LA, Oja J, Schultz L.  A prospective trial demonstrating LMWH (Dalteparin) requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.  Am J Obstet Gynecol 2004;191:1024-9. PUBMED

·         Barbour LA, Shao J, Qiao J.  Human placental growth hormone increases expression of the p85α regulatory unit of PI 3-kinase and triggers severe insulin resistance in muscle.  Endocrinology 2004;145:1144-50. PUBMED

·         Barbour LA.  New concepts in insulin resistance of pregnancy and gestational diabetes:  long-term implications for mother and offspring.  J Obstet Gynaecol 2003;23(5)545-9. PUBMED

·         Barbour, LA, Shao J, Qiao, L, Pulawa LK, Jensen DR, Bartke A, Garrity M, Draznin B, Friedman JE. Human Placental Growth Hormone Causes Severe Insulin Resistance in Transgenic Mice. Am J Obstet Gynecol 2002;186;512-7. PUBMED